COMP <GO>
ZLAB vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Zai Lab Limited (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ZLAB 1
— JNJ 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ
LAST: $22.07 (-1.30%) • MKT CAP: $2.51B
balance-sheet
0.52
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZLAB VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZLAB | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 58.30% | 67.90% | -9.60 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.33% | 2.97% | -9.30 | JNJ | /fcf-yield <GO> |
| Operating Margin | -50.20% | 34.70% | -84.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -38.40% | 28.50% | -66.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 15.00% | 6.00% | +9.00 | ZLAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.52 | 5.59 | -5.07 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.0 | 62.1 | -20.10 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.51B | $662.49B | -$659.98B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZLAB REV | JNJ REV | ZLAB GROSS % | JNJ GROSS % | ZLAB FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $457.2M | $94.19B | 58.3% | 67.9% | -$158.9M | $19.70B |
| FY 2024 | $397.6M | $88.82B | 63.0% | 69.1% | -$220.5M | $19.84B |
| FY 2023 | $266.7M | $85.16B | — | — | -$198.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZLAB // BETA —
JNJ // BETA 1.08